信達生物(01801.HK)第四季度總產品收入超16億元 同比勁增超65%
格隆匯2月6日丨信達生物(01801.HK)公佈,於2023年第四季度,公司共取得總產品收入超人民幣16億元,同比取得超65%的強勁增長,並持續採用有效的管理方法提升產出和效率,鞏固良性的運營模式。於季度內,達伯舒®(信迪利單抗注射液)廣闊的適應症及國家醫保覆蓋持續拉動銷量快速增長,市場領先地位加強;產品組合愈加多元化,其他產品整體亦保持顯著增長。
同時,公司致力於打造腫瘤領域與綜合產品線(涵蓋心血管及代謝("CVM")、自身免疫、眼科領域)豐富的產品組合和品牌價值,於季度內穩步推進CVM領域的商業化佈局,助力公司長期成長。
於季度內,達伯舒®(信迪利單抗注射液)新增第七項適應症及達攸同®(貝伐珠單抗注射液)新增第八項適應症納入2023年版國家醫保藥品目錄,是中國唯一獲批用於EGFR-TKI治療失敗非小細胞肺癌的醫保PD-1抑制劑和醫保貝伐珠單抗。新版國家醫保藥品目錄已於2024年1月1日起正式實施,患者用藥可及性進一步提高。耐立克®(奧雷巴替尼片)於季度內獲批新適應症,惠及更廣泛的慢性髓細胞白血病(CML)患者。此外,公司2款創新腫瘤靶向藥物IBI-344(ROS1抑制劑)和IBI-351(KRASG12C抑制劑)的新藥上市申請("NDA")獲國家藥品監督管理局("NMPA")受理並授予優先審評資格,商業化產品組合豐富度和協同價值有望持續提升。
公司已建立起一條擁有涵蓋癌症、CVM、自身免疫、眼科及其他主要治療領域的逾30款新藥品種的創新產品管線。截至目前,公司已取得十款產品獲批上市,同時還有2個品種的NDA在NMPA審評中,5個新藥分子進入III期或關鍵性臨牀研究,另外約20個新藥品種已進入臨牀研究。公司相信,其豐厚多元化的創新管線資產具有廣闊的市場潛力,為公司長期可持續成長提供堅實基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.